Archive for January 23rd, 2010

The U.S. Food and Drug Administration approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use…

EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced the online publication of the results from the CLARITY(1) Phase III trial using Cladribine Tablets (EMD Serono’s proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine(2)…